MX2010002679A - Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. - Google Patents
Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.Info
- Publication number
- MX2010002679A MX2010002679A MX2010002679A MX2010002679A MX2010002679A MX 2010002679 A MX2010002679 A MX 2010002679A MX 2010002679 A MX2010002679 A MX 2010002679A MX 2010002679 A MX2010002679 A MX 2010002679A MX 2010002679 A MX2010002679 A MX 2010002679A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- deuterated
- treatment
- hiv infection
- oxoquinoline
- Prior art date
Links
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical class COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003586 elvitegravir Drugs 0.000 abstract 1
- 239000003084 hiv integrase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos novedosos que son derivados de 4-axoquinolina y a las sales de los mismos farmacéuticamente aceptables. Más específicamente, esta invención se refiere a nuevos derivados de 4-axoquinolina que son derivados de elvitegravir. Esta invención también proporciona composiciones libres de pirógenos que comprenden uno o más compuestos de la invención y un portador, y al uso de los compuestos y composiciones descritos en los métodos de tratamiento de las enfermedades y afecciones que son tratadas benéficamente por la administración de un inhibidor de la integrasa de VIH, tal como elvitegravir.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99342807P | 2007-09-12 | 2007-09-12 | |
| PCT/US2008/010662 WO2009035662A1 (en) | 2007-09-12 | 2008-09-12 | Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010002679A true MX2010002679A (es) | 2010-03-29 |
Family
ID=40070844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010002679A MX2010002679A (es) | 2007-09-12 | 2008-09-12 | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7994194B2 (es) |
| EP (1) | EP2197847B1 (es) |
| AU (1) | AU2008299931B2 (es) |
| CA (1) | CA2698825C (es) |
| ES (1) | ES2406479T3 (es) |
| MX (1) | MX2010002679A (es) |
| WO (1) | WO2009035662A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3406596A1 (en) * | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MX2010002679A (es) | 2007-09-12 | 2010-03-29 | Concert Pharmaceuticals Inc | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. |
| CN102985537B (zh) | 2010-01-08 | 2015-11-25 | 阿迈瑞斯公司 | 生产粘康酸和粘康酸盐的异构体的方法 |
| CN103819402B (zh) * | 2012-11-17 | 2016-03-30 | 上海迪赛诺化学制药有限公司 | 埃替拉韦中间体及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704035A (en) * | 1986-10-06 | 1987-11-03 | Baker Perkins, Inc. | Remotely transmitting batch mixer |
| US4962495A (en) * | 1988-10-03 | 1990-10-09 | Lucas Aerospace Power Transmission Corp. | Apparatus and method for transmitting condition data from a rotating member to a stationary device |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| FR2753648B1 (fr) * | 1996-09-26 | 1998-11-27 | Alphacan Sa | Procede et installation de fabrication de tubes en matiere plastique avec etirage bi-axial, et tube en matiere plastique ainsi obtenu |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| EP3406596A1 (en) | 2002-11-20 | 2018-11-28 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| JP2009511481A (ja) | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤 |
| WO2007089030A1 (en) | 2006-02-01 | 2007-08-09 | Japan Tobacco Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| EP2059241A1 (en) | 2006-09-05 | 2009-05-20 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| MX2010002679A (es) | 2007-09-12 | 2010-03-29 | Concert Pharmaceuticals Inc | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. |
-
2008
- 2008-09-12 MX MX2010002679A patent/MX2010002679A/es active IP Right Grant
- 2008-09-12 EP EP08830735A patent/EP2197847B1/en not_active Not-in-force
- 2008-09-12 ES ES08830735T patent/ES2406479T3/es active Active
- 2008-09-12 WO PCT/US2008/010662 patent/WO2009035662A1/en not_active Ceased
- 2008-09-12 CA CA2698825A patent/CA2698825C/en not_active Expired - Fee Related
- 2008-09-12 US US12/283,620 patent/US7994194B2/en active Active
- 2008-09-12 AU AU2008299931A patent/AU2008299931B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008299931A1 (en) | 2009-03-19 |
| CA2698825C (en) | 2013-08-20 |
| US7994194B2 (en) | 2011-08-09 |
| US20090143427A1 (en) | 2009-06-04 |
| EP2197847A1 (en) | 2010-06-23 |
| CA2698825A1 (en) | 2009-03-19 |
| AU2008299931B2 (en) | 2013-01-10 |
| ES2406479T3 (es) | 2013-06-07 |
| EP2197847B1 (en) | 2012-11-07 |
| WO2009035662A1 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| PH12018502489A1 (en) | Antiviral therapy | |
| MY207716A (en) | Hiv inhibitor compounds | |
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
| TN2015000121A1 (en) | Gdf-8 inhibitors | |
| WO2009055006A8 (en) | Deuterated darunavir | |
| UA98373C2 (ru) | Конденсированные гетероциклические производные и их применение как c-met ингибиторов | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| TW200806299A (en) | Treatment of pain | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
| MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
| IN2012DN01684A (es) | ||
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| TW200639159A (en) | Treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |